The deal will see Wacker Biosolutions add 800m
“The acquisition is an important step for Wacker to securely meet our customers’ growing demand for cysteine,” spokeswoman Nadine Baumgartl told this publication.
Cysteine is used in a number of pharmaceutical functions, for example as an expectorant in cough medicines, but Baumgartl was unable to divulge how much of its capacity is used for pharma products.
She did, however, say Wacker intends to invest around €30m ($31m) to modernise the facility and add some extra production equipment over the next few years. This will create around 35 new jobs.
While not alone in making cysteine by fermentation, Baumgartl told us Wacker was the first to do so using its patented bioprocess.
“Traditionally, cysteine is extracted from human hair, pig bristles and feathers. However, this manufacturing process, which involves hydrolysis with hydrochloric acid, fractional crystallization and electrolysis, is inefficient and not particularly environmentally friendly,” she said.
Instead, Wacker uses a fermentative production method for cysteine from plant-based raw materials that utilises E. coli bacteria which she said made production extremely efficient.
“This method is extremely efficient and environmentally compatible. 90% of the bacterial cysteine ends up in the final product, compared with the 60% yield of conventional methods.
“Another advantage is that only one kilogram of hydrochloric acid is needed per kilogram of cysteine, whereas traditional processes using animal or human raw materials require 27 kg of hydrochloric acid. This represents a saving of 96%.”